Neuphoria Therapeutics (NEUP) stock was down 67% in recent Tuesday premarket activity after the company said overnight that a phase 3 trial of BNC210 for the acute treatment of social anxiety disorder did not meet its primary endpoint.

Galapagos (GLPG) shares were down 13% after the company said it decided to wind down its cell therapy operations.

Newmont (NEM) stock was 4% lower, erasing Monday's gain.

PulteGroup (PHM) shares were down 2.1% after the company posted lower Q3 earnings and revenue.